FULL TEST BANK FOR PHARMACOLOGY A PATIENT-CENTERED NURSING
PROCESS APPROACH 11TH EDITION BY LINDA E. MCCUISTION; JENNIFER J.
YEAGER; MARY B. WINTON;KATHLEEN DIMAGGIO CHAPTER 1-58 COMPLETE
GUIDE A+
,Table of Contents
Chapter 01: The Nursing Process and Patient-Centered Care .................................................... 4
Chapter 02: Drug Development and Ethical Considerations .................................................... 10
Chapter 03: Pharmacokinetics and Pharmacodynamics........................................................... 20
Chapter 04: Pharmacogenetics ................................................................................................. 39
Chapter 05: Complementary and Alternative Therapies .......................................................... 43
Chapter 06: Pediatric Considerations ....................................................................................... 50
Chapter 07: Geriatric Considerations ........................................................................................ 59
Chapter 08: Drugs in Substance Use Disorder .......................................................................... 66
Chapter 09: Safety and Quality ................................................................................................. 73
Chapter 10: Drug Administration .............................................................................................. 81
Chapter 11: Drug Calculations................................................................................................... 88
Chapter 12: Fluid Volume and Electrolytes ............................................................................... 93
Chapter 13: Vitamin and Mineral Replacement ..................................................................... 105
Chapter 14: Nutritional Support ............................................................................................. 115
Chapter 15: Adrenergic Agonists and Antagonists ................................................................. 125
Chapter 16: Cholinergic Agonists and Antagonists ................................................................. 133
Chapter 17: Stimulants ............................................................................................................ 141
Chapter 18: Depressants ......................................................................................................... 147
Chapter 19: Antiseizure Drugs ................................................................................................ 156
Chapter 20: Drugs for Parkinsonism and Alzheimer Disease .................................................. 165
Chapter 21: Drugs for Neuromuscular Disorders and Muscle Spasms ................................... 173
Chapter 22: Antipsychotics and Anxiolytics ............................................................................ 181
Chapter 23: Antidepressants and Mood Stabilizers ................................................................ 191
Chapter 24: Antiinflammatories.............................................................................................. 200
Chapter 25: Analgesics ............................................................................................................ 209
Chapter 26: Penicillins, Other Beta-Lactams, and Cephalosporins......................................... 218
Chapter 27: Macrolides, Oxazolidinones, Lincosamides, Glycopeptides, Ketolides, and
Lipopeptides ............................................................................................................................ 225
Chapter 28: Tetracyclines, Glycylcyclines, Aminoglycosides, and Fluoroquinolones mccuistion:
................................................................................................................................................. 230
Chapter 29: Sulfonamides and Nitroimidazoles Antibiotics ................................................... 235
,Chapter 30: Antituberculars, Antifungals, and Antivirals ....................................................... 241
Chapter 31: Antimalarials, Anthelmintics, and Peptides ........................................................ 252
Chapter 32: HIV- and AIDS-Related Drugs .............................................................................. 257
Chapter 33: Transplant Drugs ................................................................................................. 262
Chapter 34: Vaccines ............................................................................................................... 265
Chapter 35: Anticancer Drugs ................................................................................................. 271
Chapter 36: Targeted Therapies to Treat Cancer.................................................................... 277
Chapter 37: Biologic Response Modifiers ............................................................................... 282
Chapter 38: Upper Respiratory Disorders ............................................................................... 289
Chapter 39: Lower Respiratory Disorders ............................................................................... 296
Chapter 40: Cardiac Glycosides, Antianginals, and Antidysrhythmics .................................... 306
Chapter 41: Diuretics............................................................................................................... 319
Chapter 42: Antihypertensives................................................................................................ 325
Chapter 43: Anticoagulants, Antiplatelets, and Thrombolytics .............................................. 334
Chapter 44: Antihyperlipidemics and Drugs to Improve Peripheral Blood Flow mccuistion: 345
Chapter 45: Gastrointestinal Tract Disorders ......................................................................... 353
Chapter 46: Antiulcer Drugs .................................................................................................... 364
Chapter 47: Eye and Ear Disorders.......................................................................................... 375
Chapter 48: Dermatologic Disorders....................................................................................... 381
Chapter 49: Pituitary, Thyroid, Parathyroid, and Adrenal Disorders ...................................... 388
Chapter 50: Antidiabetics ........................................................................................................ 400
Chapter 51: Urinary Disorders ................................................................................................ 410
Chapter 52: Pregnancy and Preterm Labor............................................................................. 418
Chapter 53: Labor, Delivery, and Postpartum ........................................................................ 429
Chapter 54: Neonatal and Newborn ....................................................................................... 437
Chapter 55: Women’s Reproductive Health ........................................................................... 440
Chapter 56: Men’s Health and Reproductive Disorders ......................................................... 450
Chapter 57: Sexually Transmitted Infections .......................................................................... 457
Chapter 58: Adult and Pediatric Emergency Drugs ................................................................. 461
, Chapter 01: The Nursing Process and Patient-Centered Care
Mccuistion: Pharmacology: A Patient-Centered Nursing Process Approach, 11th Edition
MULTIPLE CHOICE
1. All of the following would be considered subjective data, EXCEPT:
A. Patient-reported health history
B. Patient-reported signs and symptoms of their illness
C. Financial barriers reported by the patient’s caregiver
D. Vital signs obtained from the medical record
ANSWER:D
Subjective data is based on what patients or family members communicate to the nurse.
Patient- reported health history, signs and symptoms, and caregiver reported financial barriers
would be considered subjective data. Vital signs obtained from the medical record would be
considered objective data.
2. The nurse is using data collected to define a set of interventions to achieve the most
desirable outcomes. Which of the following steps is the nurse applying?
A. Recognizing cues (assessment)
B. Analyze cues & prioritize hypothesis (analysis)
C. Generate solutions (planning)
D. Take action (nursing interventions)
ANSWER:C
When generating solutions (planning), the nurse identifies expected outcomes and uses the
patient’s problem(s) to define a set of interventions to achieve the most desirable outcomes.
Recognizing cues (assessment) involves the gathering of cues (information) from the patient
about their health and lifestyle practices, which are important facts that aid the nurse in making
clinical care decisions. Prioritizing hypothesis is used to organize and rank the patient
PROCESS APPROACH 11TH EDITION BY LINDA E. MCCUISTION; JENNIFER J.
YEAGER; MARY B. WINTON;KATHLEEN DIMAGGIO CHAPTER 1-58 COMPLETE
GUIDE A+
,Table of Contents
Chapter 01: The Nursing Process and Patient-Centered Care .................................................... 4
Chapter 02: Drug Development and Ethical Considerations .................................................... 10
Chapter 03: Pharmacokinetics and Pharmacodynamics........................................................... 20
Chapter 04: Pharmacogenetics ................................................................................................. 39
Chapter 05: Complementary and Alternative Therapies .......................................................... 43
Chapter 06: Pediatric Considerations ....................................................................................... 50
Chapter 07: Geriatric Considerations ........................................................................................ 59
Chapter 08: Drugs in Substance Use Disorder .......................................................................... 66
Chapter 09: Safety and Quality ................................................................................................. 73
Chapter 10: Drug Administration .............................................................................................. 81
Chapter 11: Drug Calculations................................................................................................... 88
Chapter 12: Fluid Volume and Electrolytes ............................................................................... 93
Chapter 13: Vitamin and Mineral Replacement ..................................................................... 105
Chapter 14: Nutritional Support ............................................................................................. 115
Chapter 15: Adrenergic Agonists and Antagonists ................................................................. 125
Chapter 16: Cholinergic Agonists and Antagonists ................................................................. 133
Chapter 17: Stimulants ............................................................................................................ 141
Chapter 18: Depressants ......................................................................................................... 147
Chapter 19: Antiseizure Drugs ................................................................................................ 156
Chapter 20: Drugs for Parkinsonism and Alzheimer Disease .................................................. 165
Chapter 21: Drugs for Neuromuscular Disorders and Muscle Spasms ................................... 173
Chapter 22: Antipsychotics and Anxiolytics ............................................................................ 181
Chapter 23: Antidepressants and Mood Stabilizers ................................................................ 191
Chapter 24: Antiinflammatories.............................................................................................. 200
Chapter 25: Analgesics ............................................................................................................ 209
Chapter 26: Penicillins, Other Beta-Lactams, and Cephalosporins......................................... 218
Chapter 27: Macrolides, Oxazolidinones, Lincosamides, Glycopeptides, Ketolides, and
Lipopeptides ............................................................................................................................ 225
Chapter 28: Tetracyclines, Glycylcyclines, Aminoglycosides, and Fluoroquinolones mccuistion:
................................................................................................................................................. 230
Chapter 29: Sulfonamides and Nitroimidazoles Antibiotics ................................................... 235
,Chapter 30: Antituberculars, Antifungals, and Antivirals ....................................................... 241
Chapter 31: Antimalarials, Anthelmintics, and Peptides ........................................................ 252
Chapter 32: HIV- and AIDS-Related Drugs .............................................................................. 257
Chapter 33: Transplant Drugs ................................................................................................. 262
Chapter 34: Vaccines ............................................................................................................... 265
Chapter 35: Anticancer Drugs ................................................................................................. 271
Chapter 36: Targeted Therapies to Treat Cancer.................................................................... 277
Chapter 37: Biologic Response Modifiers ............................................................................... 282
Chapter 38: Upper Respiratory Disorders ............................................................................... 289
Chapter 39: Lower Respiratory Disorders ............................................................................... 296
Chapter 40: Cardiac Glycosides, Antianginals, and Antidysrhythmics .................................... 306
Chapter 41: Diuretics............................................................................................................... 319
Chapter 42: Antihypertensives................................................................................................ 325
Chapter 43: Anticoagulants, Antiplatelets, and Thrombolytics .............................................. 334
Chapter 44: Antihyperlipidemics and Drugs to Improve Peripheral Blood Flow mccuistion: 345
Chapter 45: Gastrointestinal Tract Disorders ......................................................................... 353
Chapter 46: Antiulcer Drugs .................................................................................................... 364
Chapter 47: Eye and Ear Disorders.......................................................................................... 375
Chapter 48: Dermatologic Disorders....................................................................................... 381
Chapter 49: Pituitary, Thyroid, Parathyroid, and Adrenal Disorders ...................................... 388
Chapter 50: Antidiabetics ........................................................................................................ 400
Chapter 51: Urinary Disorders ................................................................................................ 410
Chapter 52: Pregnancy and Preterm Labor............................................................................. 418
Chapter 53: Labor, Delivery, and Postpartum ........................................................................ 429
Chapter 54: Neonatal and Newborn ....................................................................................... 437
Chapter 55: Women’s Reproductive Health ........................................................................... 440
Chapter 56: Men’s Health and Reproductive Disorders ......................................................... 450
Chapter 57: Sexually Transmitted Infections .......................................................................... 457
Chapter 58: Adult and Pediatric Emergency Drugs ................................................................. 461
, Chapter 01: The Nursing Process and Patient-Centered Care
Mccuistion: Pharmacology: A Patient-Centered Nursing Process Approach, 11th Edition
MULTIPLE CHOICE
1. All of the following would be considered subjective data, EXCEPT:
A. Patient-reported health history
B. Patient-reported signs and symptoms of their illness
C. Financial barriers reported by the patient’s caregiver
D. Vital signs obtained from the medical record
ANSWER:D
Subjective data is based on what patients or family members communicate to the nurse.
Patient- reported health history, signs and symptoms, and caregiver reported financial barriers
would be considered subjective data. Vital signs obtained from the medical record would be
considered objective data.
2. The nurse is using data collected to define a set of interventions to achieve the most
desirable outcomes. Which of the following steps is the nurse applying?
A. Recognizing cues (assessment)
B. Analyze cues & prioritize hypothesis (analysis)
C. Generate solutions (planning)
D. Take action (nursing interventions)
ANSWER:C
When generating solutions (planning), the nurse identifies expected outcomes and uses the
patient’s problem(s) to define a set of interventions to achieve the most desirable outcomes.
Recognizing cues (assessment) involves the gathering of cues (information) from the patient
about their health and lifestyle practices, which are important facts that aid the nurse in making
clinical care decisions. Prioritizing hypothesis is used to organize and rank the patient
